ATTAIN-2 trial results

Adults with overweight or obesity and type 2 diabetes.

Foundayo

Phase: Phase 3
Follow-up: 72 weeks
Randomised: 1,613
Sponsor: Eli Lilly
Publication: The Lancet · 2025

Double-blind, placebo-controlled. Treatment-regimen analysis. Orforglipron was studied as capsules.

Mean body weight change at 72 weeks

Orforglipron 6 mg−5.1%
Orforglipron 12 mg−7.0%
Orforglipron 36 mg−9.6%
Placebo−2.5%

Mean body weight change at 72 weeks
Trial arm	Result
Orforglipron 6 mg	−5.1%
Orforglipron 12 mg	−7.0%
Orforglipron 36 mg	−9.6%
Placebo	−2.5%

Safety. In the safety analysis, adverse events led 6.1%, 10.6% and 10.6% of participants in the respective orforglipron groups and 4.6% of the placebo group to stop the study drug.

Published paper PubMed abstract NCT05872620